ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2010-04-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT01088919
ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01083888
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 412
- Registration Number
- NCT01071850
- Locations
- 🇺🇸
CSRA Partners in Health, Inc., Augusta, Georgia, United States
🇺🇸Atlanta Vascular Research Foundation, Atlanta Cardiology & Primary Care P.C., Tucker, Georgia, United States
🇮🇳Bride, Bharti Hospital, Karnal, India
Liver Transplant European Study Into the Prevention of Fungal Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 350
- Registration Number
- NCT01058174
A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 110
- Registration Number
- NCT01057407
A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 130
- Registration Number
- NCT01057628
A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 182
- Registration Number
- NCT01054092
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1126
- Registration Number
- NCT01043666
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2013-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 101
- Registration Number
- NCT01038804
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇧🇪Sint-Augustinus GZA Ziekenhuizen, Wilrijk, Belgium
🇺🇸Bay Area Cancer Research Group, Pleasant Hill, California, United States
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01029015
© Copyright 2024. All Rights Reserved by MedPath